Cheryl L. Rowe-Rendleman

Dr. Cheryl Rowe-Rendleman, as Aviceda Senior Vice President in charge of regulatory affairs and clinical operations, brings 20+ years of progressive experience driving preclinical research, clinical development, and strategic communications for groundbreaking drugs and medical devices as a regulatory and clinical senior executive with subject matter expertise in ophthalmology.

Prior to that she served as CEO and managing consultant of Omar Consulting Group, LLC (Princeton NJ ǀ Durham, NC) for 16 years. Omar (ophthalmic management and research) is a practice that specializes in regulatory and clinical consulting for drugs and devices in the US, Europe, and China. At Omar, Cheryl specialized in taking companies to the regulatory health authorities (FDA, EMA) and played a leading role in developing successful paths to market and acquisition for emerging biotechnology.

Cheryl has extensive experience regulatory strategy and submissions (INDs, NDAs), strategic publications planning and content development, in translational science, pharmacology, clinical program design and execution, key opinion leader and advisory board management, and target product profile development. Cheryl led 100+ clinical stage and medical education programs in a variety of therapeutic areas; 10 NDAs, 3 patents; several 510K devices in review at the FDA; extensive publication record.

Cheryl graduated from Princeton University where she studied chemical engineering and biology with a focus in neuroscience. She completed her doctorate in biochemical and biophysical sciences at the University of Houston and completed postdoctoral training fellowships in developmental and degenerative eye diseases at respectively, the University of Texas and the University of San Francisco Medical Schools.

Chery has served as an independent director specializing in governance on industrial and foundation boards, held numerous positions in industry, and published manuscripts where she has demonstrated responsibility for driving research and development for different types of drugs and devices that treat diseases including those that cause blindness over the past 25 years. She was named co-inventor on 3 US patents in ophthalmic drug delivery and had designed over 50 clinical trials in the past 10 years in a variety of therapeutics areas.